Recently, Charles River Laboratories—a provider of products and services for drug research and development—presented a webinar about starting material for manufacturing cell therapies. Scott R. Burger ...
Induced pluripotent stem cells (iPSCs) are a “starting material grail” for advanced therapies. That’s according to Sven Kili, chief development officer at CCRM, the Canadian regenerative medicine ...
100% starting materials identification testing is a requirement according to the US FDA’s directive 211.84 for FDA-regulated industries such as Vaccines, Tobacco, Pharmaceutical, Food, Cosmetics, ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE:CRL) today announced the launch of their new CliniPrime TM suite of Good Manufacturing Practice (GMP)-compliant ...
According to the Alliance for Regenerative Medicine, more than 1300 clinical studies for regenerative medicine and advanced therapies, including autologous and allogeneic cell therapies, are ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results